Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia

Mason, Kylie D.; Sharpe, Chia; Davis, Joanne E.; Koldej, Rachel; Tam, Constantine S.; Ritchie, David

doi:10.1002/hon.2439_148

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, the combination of rituximab or GA101 with venetocax was associated with longer progression-free survival and undetectable minimal residual disease [25,26]. Intriguingly, both ibrutinib and venetoclax induce a significant increase in the frequency of γδ T cells [27], which are cytotoxic cells that share several NK-cell features such as CD16 expression and ADCC. In a very recent report, Hoeres et al demonstrated that both T and NK cells contribute to GA101-induced ADCC in an elegant and interestingly basic study [28].…”

Section: Discussionmentioning

confidence: 99%

Battle of Thermopylae: 300 Spartans (natural Killer Cells Plus obinutuzumab) Versus the Immortal Warriors (chronic Lymphocytic Leukemia cells) of Xerxes’ Army

et al. 2019

View full text Add to dashboard Cite

Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients. Patients & methods: The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry. Results: We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment. During maintenance treatment with subcutaneous rituximab, an NK cell reduction was less pronounced than after intravenous rituximab treatment, despite lymphokine-activated killer cell infusions. Conclusion: After one dose of obinutuzumab, each NK cell in peripheral blood destroys 25 leukemic cells.

show abstract